Análise do gene E6 de HPV de baixo risco em papilomatose de laringe

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Infecção congênita pelo citomegalovírus: estudo realizado na Fundação Santa Casa de Misericórdia do Pará

O citomegalovírus é um vírus de DNA, pertencente à família Herpesviridae, subfamília Beta-herpesvirinae. Sua distribuição é universal e pode causar infecções congênitas e perinatais, assim como durante a infância e na idade adulta. É um dos principais patógenos responsáveis pela morbidade e mortalidade em pacientes imunocomprometidos. Foi estudada a incidência da infecção congênita pelo citomegalovírus, na maternidade da Fundação Santa Casa Misericórdia do Pará, no período de novembro de 1994 a maio de 1995. A amostra trabalhada constou de 663 recém-nascidos e suas respectivas mães. O peso dos recém-nascidos variou de 900 a 5450 g, com uma média de 3046g. Em 11,4% das crianças foi observado baixo peso ao nascer. A avaliação pelo isolamento do vírus da saliva dos 663 recém-nascidos, através da inoculação em células primárias de fibroblasto de prepúcio humano, mostrou 3,2% (21) de positividade. A pesquisa de anticorpos IgM específicos para o CMV, através do método ELISA, utilizando-se sangue do cordão umbilical do mesmo grupo de recém-nascidos foi positiva em 2,1% (14). Para o diagnóstico da infecção congênita pelo CMV, a análise estatística pelo Teste de McNemar dos Pares Discordantes (p)=0,0233 e Teste do Qui-Quadrado da Homogeneidade (p)<0,01 demonstrou que o isolamento do citomegalovírus da saliva foi mais sensível que a detecção de anticorpos IgM no sangue do cordão umbilical. Dos 21 recém-nascidos infectados, 28,5% (6) apresentaram nas primeiras 24 horas de vida, sintomatologia sugestiva de infecção congênita. Os sinais e sintomas encontrados foram microcefalia (4), prematuridade (3), hepatoesplenomegalia (2), pequeno para a idade gestacional (2) e icterícia precoce (1). A pesquisa de anticorpos IgG específicos para o CMV, pelo método ELISA, foi positiva em 90,2% das puérperas. Das 21 mulheres que transmitiram o vírus para o concepto, foram detectados anticorpos IgM em 4. A entrevista pessoal com as mães dos recém-nascidos revelou nível socioeconômico baixo e assistência pré-natal deficiente, com 26,4% das puérperas sem nenhuma consulta durante o período gestacional. Em nossa amostra, a idade materna variou de 12 a 42 anos, com idade média de 22,2 anos, sendo que a idade das mães dos recém-nascidos infectados foi inferior a 25 anos.

Análise integrada entre dados de expressão global de transcritos codificadores e de miRNAs em carcinomas de células escamosas de laringe

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Modularity and evolutionary constraints in a baculovirus gene regulatory network

Abstract Background The structure of regulatory networks remains an open question in our understanding of complex biological systems. Interactions during complete viral life cycles present unique opportunities to understand how host-parasite network take shape and behave. The Anticarsia gemmatalis multiple nucleopolyhedrovirus (AgMNPV) is a large double-stranded DNA virus, whose genome may encode for 152 open reading frames (ORFs). Here we present the analysis of the ordered cascade of the AgMNPV gene expression. Results We observed an earlier onset of the expression than previously reported for other baculoviruses, especially for genes involved in DNA replication. Most ORFs were expressed at higher levels in a more permissive host cell line. Genes with more than one copy in the genome had distinct expression profiles, which could indicate the acquisition of new functionalities. The transcription gene regulatory network (GRN) for 149 ORFs had a modular topology comprising five communities of highly interconnected nodes that separated key genes that are functionally related on different communities, possibly maximizing redundancy and GRN robustness by compartmentalization of important functions. Core conserved functions showed expression synchronicity, distinct GRN features and significantly less genetic diversity, consistent with evolutionary constraints imposed in key elements of biological systems. This reduced genetic diversity also had a positive correlation with the importance of the gene in our estimated GRN, supporting a relationship between phylogenetic data of baculovirus genes and network features inferred from expression data. We also observed that gene arrangement in overlapping transcripts was conserved among related baculoviruses, suggesting a principle of genome organization. Conclusions Albeit with a reduced number of nodes (149), the AgMNPV GRN had a topology and key characteristics similar to those observed in complex cellular organisms, which indicates that modularity may be a general feature of biological gene regulatory networks.

Parvovirus 4 infection and clinical outcome in high-risk populations

Parvovirus 4 (PARV4) is a DNA virus frequently associated with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections, but its clinical significance is unknown. We studied the prevalence of PARV4 antibodies in 2 cohorts of HIV- and HCV-infected individuals (n = 469) and the correlations with disease status. We found that PARV4 infection frequently occurred in individuals exposed to bloodborne viruses (95% in HCV-HIV coinfected intravenous drug users [IDUs]). There were no correlations between PARV4 serostatus and HCV outcomes. There was, however, a significant association with early HIV-related symptoms, although because this was tightly linked to both HCV status and clinical group (IDU), the specific role of PARV4 is not yet clear.

Phylogeny of mRNA capping enzymes

The m7GpppN cap structure of eukaryotic mRNA is formed cotranscriptionally by the sequential action of three enzymes: RNA triphosphatase, RNA guanylyltransferase, and RNA (guanine-7)-methyltransferase. A multifunctional polypeptide containing all three active sites is encoded by vaccinia virus. In contrast, fungi and Chlorella virus encode monofunctional guanylyltransferase polypeptides that lack triphosphatase and methyltransferase activities. Transguanylylation is a two-stage reaction involving a covalent enzyme-GMP intermediate. The active site is composed of six protein motifs that are conserved in order and spacing among yeast and DNA virus capping enzymes. We performed a structure–function analysis of the six motifs by targeted mutagenesis of Ceg1, the Saccharomyces cerevisiae guanylyltransferase. Essential acidic, basic, and aromatic functional groups were identified. The structural basis for covalent catalysis was illuminated by comparing the mutational results with the crystal structure of the Chlorella virus capping enzyme. The results also allowed us to identify the capping enzyme of Caenorhabditis elegans. The 573-amino acid nematode protein consists of a C-terminal guanylyltransferase domain, which is homologous to Ceg1 and is strictly conserved with respect to all 16 amino acids that are essential for Ceg1 function, and an N-terminal phosphatase domain that bears no resemblance to the vaccinia triphosphatase domain but, instead, has strong similarity to the superfamily of protein phosphatases that act via a covalent phosphocysteine intermediate.

Ihmisen papilloomaviruksen serologinen diagnostiikka kahdella eri menetelmällä mitattuna

Ihmisen papilloomavirus (HPV) on pieni kaksisäikeinen DNA-virus, joka infektoi erilaistumiseen kykeneviä ihon ja limakalvon epiteelisoluja. Virus leviää sukupuoliyhdynnän välityksellä, mutta sillä on myös muita leviämistapoja. HPV-infektio voi aiheuttaa syöpää genitaalialueiden lisäksi esimerkiksi pään ja kaulan alueella. Tutkimukseni tavoitteena oli selvittää uuden lateral flow –menetelmään perustuvan Prevo-Check-pikatestin (Abviris, Hünfelden, Saksa) herkkyyttä HPV16-vasta-aineiden osoittamiseksi seerumista. Prevo-Check-testi tehdään sormenpäästä otetusta veripisarasta tai seeruminäytteestä. Tutkimuksessa vertasin Prevo-Check-testituloksia aikaisemmin Luminex-pohjaisella menetelmällä saatuihin tuloksiin. Testit perustuvat HPV16L1-proteiinin vasta-aineiden osoittamiseen, mutta niissä käytetyt antigeenit ovat erilaisia. Luminex-menetelmässä tulokset ilmoitettiin keskifluoresenssi-intensiteettinä (MFI), ja raja positiiviselle näytteelle asetettiin arvolle 400 MFI. Prevo-Check-tulokset analysoitiin testitikun värireaktion perusteella. Tutkimusaineistona käytettiin seeruminäytteitä 34 miehestä, jotka olivat osallistuneet suomalaiseen HPV-infektion tartuntatapoja ja luonnollista taudinkulkua selvittävään tutkimukseen (HUPA). Tutkimukseeni valitut seeruminäytteet olivat Luminex-menetelmän perusteella joko pysyvästi HPV16-seropositiivisia tai juuri HPV-serokonvertoituneita. Näytteitä oli yhteensä 40. Jokainen testattiin kuudella eri näytevolyymilla. Prevo-Check-testi antoi positiivisen tuloksen vain noin 15 %:sta Luminex-menetelmällä positiivisiksi diagnosoiduista näytteistä. Näytteet, joista todettiin korkeat HPV-vasta-ainetiitterit Luminex-menetelmällä (MFI >1500), olivat positiivisia myös Prevo-Check-pikatestillä. Lisäksi Prevo-Check-testi tunnisti positiiviseksi yhden näytteen, jonka MFI oli matala (noin 600). Pieni näytevolyymi ja näytteen pitkä reagointiaika antoivat säännöllisesti negatiivisen Prevo-Check-testituloksen. Prevo-Check-testin herkkyys ei lisääntynyt, vaikka seeruminäytteen volyymi viisinkertaistettiin. Luminex- ja Prevo-Check –menetelmien herkkyyserot johtuvat todennäköisesti antigeeninä käytetyn HPV16L1–proteiinin eri muodoista ja niiden erilaisesta kyvystä sitoutua seerumin HPV-vasta-aineeseen. Lisäksi Prevo-Check-testissä seerumin HPV-vasta-aineiden annetaan sitoutua HPVL1-antigeeniin ennen näytteiden analysointia. Mikäli Prevo-Check-pikatesti osoittaisi seropositiivisuuden ainoastaan kliinisesti relevanteissa infektioissa, eli produktiivisissä ja kroonisissa HPV16-infektioissa, sillä olisi suuri merkitys HPV-tartunnan diagnosoinnissa ja leviämisen ehkäisyssä. Pikatestikäyttö edellyttää kuitenkin menetelmän jatkokehittämistä ja sen herkkyyden lisätutkimusta.

A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge

In an effort to develop a suitable DNA vaccine candidate for dengue, using dengue-3 virus (DENV-3) as a prototype, the genes coding for premembrane (prM) and envelope proteins (E) were inserted into an expression plasmid. After selecting recombinant clones containing prM/E genes, protein expression in the cell monolayer was detected by indirect immunofluorescence and immunoprecipitation assays. After selecting three vaccine candidates (pVAC1DEN3, pVAC2DEN3 and pVAC3DEN3), they were analyzed in vivo to determine their ability to induce a DENV-3-specific immune response. After three immunizations, the spleens of the immunized animals were isolated, and the cells were cultivated to measure cytokine levels by ELISA and used for lymphoproliferation assays. All of the animals inoculated with the recombinant clones induced neutralizing antibodies against DENV-3 and produced a T cell proliferation response after specific stimuli. Immunized and control mice were challenged with a lethal dose of DENV-3 and observed in order to assess their survival capability. The groups that presented the best survival rate after the challenge were the animals vaccinated with the pVAC3DEN3 clones, with an 80% survival rate. Thus, these data show that we have manufactured a vaccine candidate for DENV-3 that is able to induce a specific immune response and protects mice against a lethal challenge.

A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection

A DNA vaccine expressing dengue-4 virus premembrane (prM) and envelope (E) genes was produced by inserting these genes into a mammalian expression plasmid (pCI). Following a thorough screening, including confirmation of protein expression in vitro, a recombinant clone expressing these genes was selected and used to immunize BALB/c mice. After 3 immunizations all the animals produced detectable levels of neutralizing antibodies against dengue-4 virus. The cytokines levels and T cell proliferation, detected ex vivo from the spleen of the immunized mice, showed that our construction induced substantial immune stimulation after three doses. Even though the antibody levels, induced by our DNA vaccine, were lower than those obtained in mice immunized with dengue-4 virus the levels of protection were high with this vaccine. This observation is further supported by the fact that 80% of the vaccine immunized group was protected against lethal challenge. In conclusion, we developed a DNA vaccine employing the genes of the prM and E proteins from dengue-4 virus that protects mice against this virus. (C) 2010 Elsevier Ltd. All rights reserved.

Differentiation of field isolates and vaccine strains of infectious laryngotracheitis virus by DNA sequencing

Two different regions of the infected cell protein 4 (ICP4) gene of infectious laryngotracheitis virus (ILTV) were amplified and sequenced for characterization of field isolates and tissue culture-origin (TCO) and chicken embryo-origin (CEO) vaccine strains. Phylogenetic analysis of the two regions showed differences in nucleotide and amino acid sequences between field isolates and attenuated vaccines. The PCR-RFLP results were identical to those obtained by DNA sequencing and validated their use to differentiate ILTV strains. The approach using the sequencing of the two fragments of the ICP4 gene showed to be an efficient and practical procedure to differentiate between field isolates and vaccine strains of ILTV. (C) 2009 Elsevier Ltd. All rights reserved.

Coupling between replication and packaging of flavivirus RNA: Evidence derived from the use of DNA-based full-length cDNA clones of kunjin virus

In order to study whether flavivirus RNA packaging is dependent on RNA replication, we generated two DNA-based Kunjin virus constructs, pKUN1 and pKUN1dGDD, allowing continuous production of replicating (wild-type) and nonreplicating (with a deletion of the NS5 gene RNA-polymerase motif GDD) full-length Kunjin virus RNAs, respectively, via nuclear transcription by cellular RNA polymerase II. As expected, transfection of pKUN1 plasmid DNA into BHK cells resulted in the recovery of secreted infectious Kunjin virions. Transfection of pKUN1dGDD DNA into BHK cells, however, did not result in the recovery of any secreted virus particles containing encapsidated dGDD RNA, despite an apparent accumulation of this RNA in cells demonstrated by Northern blot analysis and its efficient translation demonstrated by detection of correctly processed labeled structural proteins (at least prM and E) both in cells and in the culture fluid using coimmunoprecipitation analysis with anti-E antibodies. In contrast, when dGDD RNA was produced even in much smaller amounts in PKUN1dGDD DNA-transfected repBHK cells (where it was replicated via complementation), it was packaged into secreted virus particles, Thus, packaging of defective Kunjin virus RNA could occur only when it was replicated. Our results with genome-length Kunjin virus RNA and the results with poliovirus replicon RNA (C, I. Nugent et al,, J, Virol, 73:427-435, 1999), both demonstrating the necessity for the RNA to be replicated before it can be packaged, strongly suggest the existence of a common mechanism for minimizing amplification and transmission of defective RNAs among the quasispecies in positive-strand RNA viruses, This mechanism may thus help alleviate the high-copy error rate of RNA-dependent RNA polymerases.

DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus

A plasmid DNA directing transcription of the infectious full-length RNA genome of Kunjin (KUN) virus in vivo from a mammalian expression promoter was used to vaccinate mice intramuscularly. The KUN viral cDNA encoded in the plasmid contained the mutation in the NS1 protein (Pro-250 to Leu) previously shown to attenuate KUN virus in weanling mice. KUN virus was isolated from the blood of immunized mice 3-4 days after DNA inoculation, demonstrating that infectious RNA was being transcribed in vivo; however, no symptoms of virus-induced disease were observed. By 19 days postimmunization, neutralizing antibody was detected in the serum of immunized animals. On challenge with lethal doses of the virulent New York strain of West Nile (WN) or wild-type KUN virus intracerebrally or intraperitoneally, mice immunized with as little as 0.1-1 mug of KUN plasmid DNA were solidly protected against disease. This finding correlated with neutralization data in vitro showing that serum from KUN DNA-immunized mice neutralized KUN and WN,viruses with similar efficiencies. The results demonstrate that delivery of an attenuated but replicating KUN virus via a plasmid DNA vector may provide an effective vaccination strategy against virulent strains of WN virus.

Comparison of serum hepatitis B virus replication markers in patients with chronic hepatitis B: studies on HBeAg/Anti-HBe system, viral dna polymerase and HBV-DNA

The detection of HBV-DNA in serum by molecular hybridization is the most sensitive and specific marker of replication and infectivity of hepatitis B virus and currently is proposed as a routine diagnostic technique in the follow-up of HBV - related diseases. Comparing different techniques already described, we found that direct spotting of serum samples on nitrocellulose membranes under vacuum filtration, followed by denaturing and neutralizing washes is more practical, simple, sensible and reproducible. DNA polymerase assay using phosphonoformic acid as specific viral inhibitor has shown 86.8% of concordance with HBV-DNA detection, and so, it is an useful alternative in the follow-up of hepatitis B chronic patients. We found 19.2% HBeAg positive samples with no other markers of viral replication and no anti-HBe positive sample had detectable HBV-DNA. Discordance between the 2 systems have been extensively described, and we confirm this for the first time in our country. Molecular biological techniques are essential to determine the replication status of chronic hepatitis B patients.

Detection of hepatitis B virus DNA by the polymerase chain reaction in anti-HBE positive chronic hepatitis B patients

Detection of HBV-DNA by PCR was compared with other serological markers (HBsAg, HBeAg and anti-HBe) in a series of49 Chronic Hepatitis B patients, including 12 with a spontaneous clearance of HBsAg. None of these HBsAg negative cases were PCR positive, but 33/37 (89.2%) HBsAg positive cases were PCR positive (p < 0.0001). Among HBsAg positive samples, nine cases were HBeAg positive and anti-HBe negative, all of them PCR positive. Other 3 patients were HBeAg and anti-HBe positive and these cases were also found PCR positive. A third group included 21 patients anti-HBe positive and HBeAg negative: 19 of them were PCR positive and 2 were PCR negative. The last 4 cases were HBeAg and anti-HBe negative, two of them were PCR positive. The detection of anti-HBe viremic cases in the present series suggest that preC variants could occur in our country. In conclusion, the integrated phase o f chronic hepatitis B seems to be less frequent than it was assumed, when only HBeAg or dot blot hybridization techniques were used. The new term "low replication phase" might favorably replace the former "integrated phase".

Seroprevalence of hepatitis B virus infection in individuals with clinical evidence of hepatitis in Goiânia, Goiás: detection of viral DNA and determination of subtypes

The presence of serological markers for hepatitis B virus (HBsAg, anti-HBc IgM and Anti-HBc total) was investigated in the serum of 1,396 individuals who had clinical suspect of hepatitis. It was observed that 50.7% of the individuals were positive and, from the total of the studied individuals, 14.5% were positive for HBsAg. From these, 8.5% were also positive for anti-HBc IgM. The analysis in relation to gender showed a higher seroprevalence index among male individuals (p < 0.0001). It was observed the occurrence of subtypes adw2 (62.7%), ayw3 (23.5%), ayw2 (9.8%) and adw4 (3.9%). The viral DNA was detected in 61 (33.9%) HBsAg positive samples and in one sample positive only for anti-HBc total. These results indicate an important incidence of the HBV infection in this population, and reinforce previous studies regarding this virus in the central west region of Brazil.